Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients.
Devon M Greer
No relevant relationships to disclose
Susanne Liewer
No relevant relationships to disclose
Mojtaba Akhtari
Consultant or Advisory Role - ARIAD